Anthraquinone-2,6-disulfonic acid as a disease-modifying osteoarthritis drug: An in vitro and in vivo study

Clinical Orthopaedics and Related Research

Volumn 461, Issue , 2007, Pages 231-237

  Savarino, Lucia ^a   Fioravanti, Antonella ^b   Leo, Graziana ^b   Aloisi, Ruggero ^c   Mian, Maurizio ^d  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Gunther Reform Holding SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 ANTHRAQUINONEDISULFONIC ACID; ANTHRAQUINONE DERIVATIVE; CATHEPSIN B; DIACETYLRHEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GR 373; INTERLEUKIN 1BETA; PROTEOGLYCAN; UNCLASSIFIED DRUG; 2,6 DISULFONIC ACID ANTHRAQUINONE; 2,6-DISULFONIC ACID ANTHRAQUINONE; RHEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARTILAGE; CARTILAGE BIOPSY; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; KNEE; MALE; MENISCECTOMY; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; PRIORITY JOURNAL; RABBIT; ANIMAL; ARTICLE; ARTICULAR CARTILAGE; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; PATHOLOGY;

ANIMALS; ANTHRAQUINONES; CARTILAGE, ARTICULAR; CATHEPSIN B; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OSTEOARTHRITIS; RABBITS;

EID: 34548324800     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e3180533b5c     Document Type: Conference Paper

References (47)

1. Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, Buckwalter J, Dougados M, Ehrlich G, Lequesne M, Lohmander S, Murphy WA Jr, Rosario-Jansen T, Schwartz B, Trippel S. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society: results from a workshop. Osteoarthritis Cartilage. 1996;4:217-243.
2. Altman RD, Dean DD. Osteoarthritis research: animal models. Semin Arthritis Rheum. 1990;19(suppl 1):21-25.
3. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975;31:347-364.
4. Baici A, Lang A, Horler D, Kissling R, Merlin C. Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann Rheum Dis. 1995;54:289-297.
5. Baici A, Lang A, Zwicky R, Muntener K. Cathepsin B in osteoarthritis: uncontrolled proteolysis uncontrolled proteolysis in the wrong place. Semin Arthritis Rheum. 2005;34(suppl 2):24-28.
6. Brandt KD. Toward pharmacologic modification of joint damage in osteoarthritis. Ann Intern Med. 1995;122:874-875.
7. Brandt KD. Studies in animal models of osteoarthritis as predictor of structure-modifying effect of diacerhein in humans with osteoarthritis. Biorheology. 2006;43:589-594.
8. Brown JP. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res. 1980;75:243-277.
9. Burkhardt D, Hwa SY, Ghosh P. A novel microassay for the quantitation of the sulfated glycosaminoglycan content of histological sections: its application to determine the effects of diacerhein on cartilage in an ovine model of osteoarthritis. Osteoarthritis Cartilage. 2001;9:238-247.
10. Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J Gastroenterol. 1997;32:127-133.
11. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 1989;84:678-685.
12. De Angelis A. Tecniche per la coltivazione delle cellule in vitro. In: Zucco F, Bianchi V, eds. Colture cellulari in tossicologia. Rome, Italy: Lombardo Editore; 1994:31-54.
13. Debord P, Louchahi K, Tod M, Cournot A, Perret G, Petitjean O. Influence of renal function on the pharmacokinetics of diacerhein after a single oral dose. Eur J Drug Metab Pharmacokinet. 1994;19:13-19.
14. de Isla NG, Yang JW, Huselstein C, Muller S, Stoltz JF. IL-1beta synthesis by chondrocytes analyzed by 3D microscopy and flow cytometry: effect of rhein. Biorheology. 2006;43:595-601.
15. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001;44:2539-2547.
16. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res. 1982;9:247-248.
17. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39:237-246.
18. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992;267:19470-19474.
19. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res. 2004;427(suppl):S27-S36.
20. Group for the Respect of Ethics and Excellence in Science (GREES). Osteoarthritis section. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 1996;55:552-557.
21. Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J Rheumatol. 1995;22:1941-1946.
22. Hwa SY, Burkhardt D, Little C, Ghosh P. The effect of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. J Rheumatol. 2001;28:825-834.
23. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M, Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003. An evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
24. Lang A, Holder D, Baici A. The relative importance of cysteine peptidases in osteoarthritis. J Rheumatol. 2000;27:1970-1979.
25. Marcolongo R, Fioravanti A, Adami S, Tozzi E, Mian M, Zampieri A. Efficacy and tolerability of diacerhein in the treatment of osteoarthritis. Curr Ther Res. 1988;43:878-887.
26. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage. 2004;12(suppl A):S31-S33.
27. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin-1 and tumor necrosis factor-alpha systems in human osteoarthritis synovium and chondrocytes. J Rheumatol. 1998;25:753-762.
28. Martel-Pelletier J, Zafarullah M, Kodama S, Pelletier JP. In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage. J Rheumatol Suppl. 1991;27:80-84.
29. Matsui H, Shimizu M, Tsuji H. Cartilage and subchondral bone interaction in osteoarthritis of human knee joint: a histological and histomorphometric study. Microsc Res Tech. 1997;37:333-342.
30. Mazières B, Blanckaert A, Thiechart M. Experimental post-contusive osteoarthritis of the knee: quantitative microscopic study of the patella and the femoral condyles. J Rheumatol. 1987;14:119-121.
31. Mehraban F, Tindal MH, Proffit MM, Moskowitz RW. Temporal pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and synovium from rabbit knees with experimental osteoarthritis: gene expression in chondrocytes in response to interleukin-1 and matrix depletion. Ann Rheum Dis. 1997;56:108-115.
32. Mian M, Benetti D, Rosini S, Fantozzi R. Rhein reduces proteoglycan loss during the autolytic breakdown of cultured cartilage. Int J Tissue React. 1989;11:117-122.
33. Mian M, Brunelleschi S, Tarli S, Rubino A, Benetti D, Fantozzi R, Zilletti L. Rhein: an anthraquinone that modulates superoxide anion production from human neutrophils. J Pharm Pharmacol. 1987;39:845-847.
34. Moore A, Greenslade K, Alam C, Willoughby D. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage. 1998;6:19-23.
35. Morales TI. Articular cartilage organ cultures: in vitro models of matrix homeostasis, resorption or repair. In: Woessner JF Jr, Howell DS, eds. Joint Cartilage Degradation. New York, NY: Marcel Dekker, Inc; 1993:261-280.
36. Moskowitz RW, Howell DS, Goldeberg VM, Muniz O, Mayor M, Pita JC. Cartilage proteoglycan alterations in an experimentally induced model of rabbit osteoarthritis. Arthritis Rheum. 1979;22:155-163.
37. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, Wigler I, Rosner IA, Beaulieu AD. Efficacy and safety of diacerhein in osteoarthritis of the knee: a double-blind placebo-controlled trial. The Diacerhein Study Group. Arthritis Rheum. 2000;43:2339-2348.
38. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989;2:519-522.
39. Richette P, Bardin T. Structure-modifying agents for osteoarthritis: an update. Joint Bone Spine. 2004;71:18-23.
40. Smith G, Myers A, Brandt K, Mickler E, Albrecht M. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate deficiency model of osteoarthritis. Arthritis Rheum. 1999;42:545-554.
41. Tamura T, Kosaka N, Ishiwa J, Sato T, Nagase H, Ito A. Rhein, an active metabolite of diacerhein, down-regulates the production of pro-matrix metalloproteinases-1,-3,-9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage. 2001;9:257-263.
42. Tamura T, Ohmori K. Rhein, an active metabolite of diacerein, suppresses the IL-1alpha- induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol. 2001;85:101-104.
43. Troyer H. Experimental models of osteoarthritis: a review. Semin Arthritis Rheum. 1982;11:362-374.
44. van Denberg WB. Osteophyte formation in osteoarthritis. Osteoarthritis Cartilage. 1999;7:333.
45. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford). 2006;45:129-138.
46. Vignon E, Mazières B, Richard M, Annefeld M. In vitro evaluation of a chondro-protector. Rev Rhum Mal Osteoartic. 1990;57:15S-18S.
47. Young AA, Smith MM, Smith SM, Cake MA, Ghosh P, Read RA, Melrose J, Sonnabend DH, Roughley PJ, Little CB. Regional assessment of cartilage gene expression and small proteoglycan metabolism in an animal model of osteoarthritis. Arthritis Res Ther. 2005;7:R852-R861.